Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-10-24, Stock:NVS, The news for the past five days is as follows:
2019-10-17: NEWS1: Novartis' Jakavi Meets Primary Goal in Phase III for GVHD.NEWS2: Roche Posts Solid Sales for First 9 Months of '19, Ups View.
2019-10-18: NEWS1: Rising tide of East Bay biotech deals promises millions of square feet.NEWS2: New Gilead CFO: Let's Make a Deal.NEWS3: Factors Setting the Tone for Novartis' (NVS) Q3 Earnings.NEWS4: Investors Beware: Tilray Stock Might Not Be Done Dropping.NEWS5: Takeda pares down products and jobs, revives Genzyme building plans.
2019-10-21: nan
2019-10-22: NEWS1: Does Novartis' Gene Therapy Stand A Chance Of Undercutting Biogen?.NEWS2: Does Novartis' Gene Therapy Stand A Chance Of Undercutting Biogen?.NEWS3: Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More.NEWS4: Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y.NEWS5: Biogen Stock Is Soaring as Hope Returns for Alzheimer’s Drug.NEWS6: Novartis data suggest payers getting breaks on gene therapy Zolgensma.NEWS7: Novartis Stock Slips Despite Strong Third-Quarter Earnings.NEWS8: Novartis net income climbs as drug sales grow.NEWS9: The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug.NEWS10: Novartis Posts Third-Quarter Earnings Beat on Strong Drug Sales.NEWS11: Novartis Earnings Top; Swiss Drug Giant Edges Lower.NEWS12: European stocks edge back from 2019 highs.NEWS13: UPDATE 2-Novartis gets lift from $2.1 mln gene therapy Zolgensma.NEWS14: Novartis hikes 2019 outlook as gene therapy, skin drugs shine.NEWS15: Novartis gets lift from $2.1 million gene therapy Zolgensma.
2019-10-23: NEWS1: Is a Beat in Store for Glaxo (GSK) This Earnings Season?.NEWS2: Novartis shells out $80M for Peninsula company's preclinical liver drug.NEWS3: Will Strong Jakafi Sales Drive Incyte's (INCY) Q3 Earnings?.NEWS4: Big Biotech Receives Some Needed Shots in the Arm.

Answer: Rise